Domestic innovative drug "unicorn" Xinnovex completes IPO counseling

Recently, Suzhou Xinuo Wei Pharmaceutical Technology Co., Ltd.'s IPO guidance status has changed to "guidance acceptance". Guiding securities Guotai Haitong Securities stated that after guidance, the company believes that the guidance target has the necessary corporate governance structure, accounting foundation, and internal control system to become a listed company.